
## Laura Beretta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3379492/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease. Hepatology, 2022, 75, 955-967.	3.6	25
2	Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 208-218.	3.7	105
3	Gut Microbiome Alterations Associated with Diabetes in Mexican Americans in South Texas. MSystems, 2022, 7, e0003322.	1.7	14
4	Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma. Abdominal Radiology, 2021, 46, 1008-1015.	1.0	10
5	A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prevention Research, 2021, 14, 667-674.	0.7	7
6	Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1643-1651.	1.1	6
7	Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prevention Research, 2021, 14, 955-962.	0.7	22
8	Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics. International Journal of Molecular Sciences, 2021, 22, 7411.	1.8	3
9	Elevated Glycated Hemoglobin Is Associated With Liver Fibrosis, as Assessed by Elastography, in a Populationâ€Based Study of Mexican Americans. Hepatology Communications, 2020, 4, 1793-1801.	2.0	17
10	Multispectral Imaging Enables Characterization of Intrahepatic Macrophages in Patients With Chronic Liver Disease. Hepatology Communications, 2020, 4, 708-723.	2.0	11
11	Bile Acid Changes Associated With Liver Fibrosis and Steatosis in the Mexicanâ€American Population of South Texas. Hepatology Communications, 2020, 4, 555-568.	2.0	26
12	High Prevalence of Hepatic Fibrosis, Measured by Elastography,Âin a Population-Based Study of Mexican Americans. Clinical Gastroenterology and Hepatology, 2019, 17, 968-975.e5.	2.4	16
13	Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature, 2019, 566, 403-406.	13.7	326
14	Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. American Journal of Gastroenterology, 2019, 114, 530-532.	0.2	27
15	Prevalence of Aflatoxin-Associated <i>TP53R249S</i> Mutation in Hepatocellular Carcinoma in Hispanics in South Texas. Cancer Prevention Research, 2018, 11, 103-112.	0.7	16
16	Depletion of S100A4+ stromal cells does not prevent HCC development but reduces the stem cell-like phenotype of the tumors. Experimental and Molecular Medicine, 2018, 50, e422-e422.	3.2	18
17	Prevalence of Aflatoxin-Associated <i>TP53R249S</i> Mutation in Hepatocellular Carcinoma in Hispanics in South Texas. Cancer Prevention Research, 2018, 11, 103-112.	0.7	19
18	Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis. Oncotarget, 2018, 9, 29495-29507.	0.8	18

LAURA BERETTA

#	Article	IF	CITATIONS
19	Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors. Hepatology Communications, 2018, 2, 718-731.	2.0	49
20	Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice. Clinical Cancer Research, 2017, 23, 5537-5546.	3.2	83
21	Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid. PLoS ONE, 2017, 12, e0189965.	1.1	35
22	The Precarious Health of Young Mexican American Men in South Texas, Cameron County Hispanic Cohort, 2004–2015. Preventing Chronic Disease, 2016, 13, E113.	1.7	15
23	Cirrhosis and Advanced Fibrosis in Hispanics in Texas: The Dominant Contribution of Central Obesity. PLoS ONE, 2016, 11, e0150978.	1.1	21
24	Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miRâ€148a on tumor growth and phenotype and liver fibrosis. Hepatology, 2016, 63, 864-879.	3.6	78
25	Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population. Cancer Prevention Research, 2016, 9, 758-765.	0.7	41
26	MicroRNA Regulates Hepatocytic Differentiation of Progenitor Cells by Targeting YAP1. Stem Cells, 2016, 34, 1284-1296.	1.4	39
27	Quantitative Contrast-Enhanced Ultrasonic Imaging Reflects Microvascularization in Hepatocellular Carcinoma and Prognosis after Resection. Ultrasound in Medicine and Biology, 2015, 41, 2621-2630.	0.7	7
28	miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells. Cancer Research, 2015, 75, 1859-1867.	0.4	83
29	Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort. World Journal of Hepatology, 2015, 7, 1586.	0.8	20
30	Proteomic and Lipidomic Signatures of Lipid Metabolism in NASH-Associated Hepatocellular Carcinoma. Cancer Research, 2013, 73, 4722-4731.	0.4	134